Heart failure

JACC: Heart Failure

Volumn 1, Issue 1, 2013, Pages 1-20

  Braunwald, Eugene ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Biomarkers; Calcium cycling; Cardiovascular disease; Heart failure; Left ventricular assist device; Review

Indexed keywords

2 [4 [3 [N (3,4 DIMETHOXYPHENETHYL) N METHYLAMINO]PROPOXY]BENZENESULFONYL] 3 ISOPROPYL 1 METHYLINDOLE; 2,3,4,5 TETRAHYDRO 7 METHOXY 4 METHYL 1,4 BENZOTHIAZEPINE; 3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; 4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; ADENOVIRUS VECTOR; ADENYLATE CYCLASE; ADENYLATE CYCLASE 6; ADRENOMEDULLIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALCIUM ION; CELL PROTEIN; COPEPTIN; CREATININE; IVABRADINE; KIDNEY INJURY MOLECULE 1; LEVOSIMENDAN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OMECAMTIV MECARBIL; PLACEBO; PLASMA PROTEIN; QUIESCIN Q6; SILDENAFIL; ST2 PROTEIN; TROPONIN I; TROPONIN T; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIC ACID; VALSARTAN; BIOLOGICAL MARKER; CALCIUM CHANNEL; CARDIOTONIC AGENT;

ACUTE HEART INFARCTION; ADENYL CYCLASE 6 GENE; AORTA STENOSIS; CALCIUM TRANSPORT; CARDIOVASCULAR MORTALITY; CELL DEATH; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; EXTRACELLULAR MATRIX; GENE; GENE THERAPY; HEALTH CARE COST; HEART CONTRACTION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE REMODELING; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MORBIDITY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STEM CELL TRANSPLANTATION; THERAPY EFFECT; ADULT; AGED; BIOLOGICAL MODEL; FEMALE; FORECASTING; HEART ASSIST DEVICE; HEART MUSCLE CELL; HEMODYNAMICS; MALE; METABOLISM; MIDDLE AGED; MYOCARDITIS; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CALCIUM CHANNELS; CARDIOTONIC AGENTS; FEMALE; FORECASTING; GENETIC THERAPY; HEART FAILURE; HEART-ASSIST DEVICES; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MYOCARDITIS; MYOCYTES, CARDIAC; STEM CELL TRANSPLANTATION; VENTRICULAR REMODELING; YOUNG ADULT;

EID: 84875987216     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2012.10.002     Document Type: Review

References (199)

1. Nabel E.G., Braunwald E. A tale of coronary artery disease and myocardial infarction. N Engl J Med 2012, 366:54-63.
2. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012, 125:e2-e220.
3. National Heart, Lung and Blood Institute. Morbidity and Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases. February 2012.
4. Chen J., Normand S.-L.T., Wang Y., Krumholz H.M. National and regional trends in hear failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA 2011, 306:1669-1678.
5. Levy D., Jenchaiah S., Larson M.G., et al. Longterm trends in the incidence of and survival with heart failure. N Engl J Med 2002, 347:1397-1402.
6. Jhund P.S., MacIntyre K., Simpson C.R., et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation 2009, 119:515-523.
7. Laribi S., Aouba A., Nikolaou M., et al. Trends in death attributed to heart failure over the past two decades in Europe. Eur J Heart Fail 2012, 14:234-239.
8. Lloyd-Jones D., Adams R.J., Brown T.M., et al. Heart disease and stroke statistics-2010 Update. Circulation 2010, 121:e46-215.
9. Dunlay S.M., Shah N.D., Shi Q., et al. Lifetime costs of medical care after heart failure diagnosis. Circ Cardiovasc Qual Outcomes 2011, 4:68-75.
10. Roger V.L. The heart failure epidemic. Int J Environ Res Public Health 2010, 7:1807-1830.
11. Askoxylakis V., Thieke C., Pleger S.T., et al. Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer 2010, 10:105.
12. Hummel S.L., Pauli N.P., Krumholz H.M., et al. Thirty-day outcomes in Medicare patients with heart failure at heart transplant centers. Circ Heart Fail 2010, 3:244-252.
13. Ross J.S., Chen J., Lin Z., et al. Recent national trends in readmission rates after heart failure hospitalizations. Circ Heart Fail 2010, 3:97-103.
14. Braunwald E. Shattuck lecture-cardiovascular medicine at the turn of the millennium. Triumphs, concerns and opportunities. N Engl J Med 1997, 337:1360-1369.
15. Mountanonakis S.E., Grau-Sepulveda M.V., Bhatt D.L., Hernandez A.F., Peterson E.D., Fonarow G.C. Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure. Circ Heart Fail 2012, 5:191-201.
16. Goyal A., Norton C.R., Thomas T.N., et al. Predictors of incident heart failure in a large insured population. A one million person-year follow-up study. Circ Heart Fail 2010, 3:698-705.
17. Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355:251-259.
18. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012, 33:1787-1847. Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure.
19. Steinberg B.A., Zhao X., Heidenreich P.A., et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction. Circulation 2012, 126:65-75.
20. Vogel M.W., Slusser J.P., Hodge D.O., Chen H.H. The natural history of preclinical diastolic dysfunction. A population-based study. Circ Heart Fail 2012, 5:144-151.
21. Kane G.C., Karon B.L., Mahoney D.W., et al. Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA 2011, 306:856-863.
22. Peacock W.F., Braunwald E., Abraham W., et al. Research challenges and opportunities. J Am Coll Cardiol 2010, 56:343-351. for the NHLBI Working Group on Emergency Department Management of Acute Heart Failure.
23. Yancy C.W., Lopatin M., Stevenson L.W., et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the National Registry (ADHERE) Database. J Am Coll Cardiol 2006, 47:76-84.
24. Katz A.M. Definition, historical aspects. Heart Failure: Pathophysiology, Molecular Biology, and Clinical Management 2008, Lippincott Williams & Wilkins, Baltimore, MD. 2nd ed. A.M. Katz, M.A. Konstam (Eds.).
25. Braunwald E., Ross J., Sonnenblick E.H. Medical progress. Mechanisms of contraction of the normal and failing heart. N Engl J Med 1967, 277:794-800. 853-63, 910-20, 962-71, 1012-22.
26. Spann J.F., Buccino R.A., Sonnenblick E.H., Braunwald E. Contractile state of cardiac muscle obtained from cats with experimentally produced ventricular hypertrophy and heart failure. Circulation Res 1967, 21:341-354.
27. van der Velden J., Klein L.J., Zaremba R., et al. Effects of calcium, inorganic phosphate, and pH on isometric force in single skinned cardiomyocytes from donor and failing human hearts. Circulation 2001, 104:1140-1146.
28. van Heerebeck L., Borbely A., Niessen H.W.M., et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006, 113:1966-1973.
29. Ohtani T., Mohammed S.F., Yamamoto K., et al. Diastolic stiffness as assessed by diastolic wall strain is associated with adverse remodeling and poor outcomes in heart failure with preserved ejection fraction. Eur Heart J 2012, 33:1742-1749.
30. Borbely A., van der Velden J., Papp Z., et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation 2005, 111:774-781.
31. Owen A.A., Spinale F.G. Myocardial basis for heart failure: role of the cardiac interstitium. Heart Failure: A Companion to Braunwald's Heart Disease 2010, 73-84. Elsevier, Philadelphia, PA. 2nd ed. D.L. Mann (Ed.).
32. Gandhi M.S., Kamalov G., Shahbaz A.U., et al. Cellular and molecular pathways to myocardial necrosis and replacement fibrosis. Heart Fail Rev 2011, 16:23-24.
33. Katz A.M., Zile M.R. New molecular mechanism in diastolic heart failure. Circulation 2006, 113:1922-1925.
34. Creemers E.E., Pinto Y.M. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res 2011, 89:265-272.
35. Braunwald E., Chidsey C.A., Harrison D.C., Gaffney T.E., Kahler R.L. Studies on the function of the adrenergic nerve endings in the heart. Circulation 1963, 28:958-969.
36. Ringer S. A further contribution regarding the influence of the different constituents of the blood on the contraction of the heart. J Physiol 1883, 4:29-42.
37. Belevych A.E., Terentyev D., Terentyeva R., et al. The relationship between arrhythmogenesis and impaired contractility in heart failure: Role of altered ryanodine receptor function. Cardiovasc Res 2011, 90:493-502.
38. Shan J., Betzenhauser M.J., Kushnir A., et al. Role of chronic ryanodine receptor phosphorylation in heart failure and beta-adrenergic receptor blockade in mice. J Clin Invest 2010, 120:4375-4387.
39. Respress J.L., van Oort R.J., Li N., et al. Role of RyR2 phosphorylation at S2814 during heart failure progression. Circ Res 2012, 110:1474-1483.
40. Chen Y., Escoubet B., Prunier F., et al. Constitutive cardiac overexpression of sarcoplasmic/endoplasmic reticulum Ca2+ATPase delays myocardial failure after myocardial infarction in rats at a cost of increased acute arrhythmias. Circulation 2004, 109:1898-1903.
41. El-Armouche A., Eschenhagen T. β-adrenergic stimulation and myocardial function in the failing heart. Heart Fail Rev 2009, 14:225-241.
42. Konstantinidis K., Whelan R.S., Kitsis R.N. Mechanisms of cell death in heart disease. Arterioscler Thromb Vasc Biol 2012, 32:1552-1562.
43. Olivetti G., Abbi R., Quaini F., et al. Apoptosis in the failing human heart. N Engl J Med 1997, 336:1131-1141.
44. Mudd J.O., Kass D.A. Tackling heart failure in the twenty-first century. Nature 2008, 451:919-928.
45. de Meyer G.R.Y., de Keulenaer G.W. Role of autophagy in heart failure associated with aging. Heart Fail Rev 2010, 15:423-430.
46. Morita H., Seidman J., Seidman C.E. Genetic causes of human heart failure. J Clin Invest 2005, 115:518.
47. Herman D.S., Lam L., Taylor M.R., et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med 2012, 366:619-628.
48. Watkins H., Ashafian H., Redwood C. Inherited cardiomyopathies. N Engl J Med 2011, 364:1643-1656.
49. Chander S., Yeo L.S., Leimena C., et al. Effects of mechanical stress and carvedilol in lamin A/C-deficient dilated cardiomyopathy. Circ Res 2010, 106:573-582.
50. Zeller T., Blankenberg S., Diemert P. Genomewide association studies in cardiovascular disease-an update 2011. Clin Chem 2012, 58:92-103.
51. Schunkert H., Konig I.R., Kathiresan S., et al. Large-scale association-analysis identifies 134 new susceptibility loci for coronary artery disease. Nat Genet 2011, 43:333-338.
52. Stark K., Esslinger U.B., Reinhard W., et al. Genetic association study identifies HSPB7 as a risk gene for idiopathic dilated cardiomyopathy. PLoS Genet 2010, 6:e1001167.
53. Villard E., Perret C., Gary F., et al. A genome-wide association study identifies to loci associated with heart failure due to dilated cardiomyopathy. Eur Heart J 2011, 32:1065-1076.
54. Almeida M.I., Reis R.M., Calin G.A. MicroRNA history: discovery, recent applications, and next frontiers. Mutat Res 2011, 717:1-8.
55. Pritchard C.C., Cheng H.H., Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet 2012, 13:358-369.
56. Care A., Catalucci C.A., Felicetti F., et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007, 13:613-618.
57. Gurha P., Abreu-Goodger C., Wang T., et al. Targeted deletion of microRNA-22 promotes stress-induced cardiac dilation and contractile dysfunction. Circulation 2012, 125:2751-2761.
58. McManus D.D., Ambros V. Circulating microRNAs in cardiovascular disease. Circulation 2011, 124:1908-1910.
59. Montgomery R.L., Hullinger T.G., Semus H.M., et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 2011, 124:1537-1547.
60. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008, 358:2148-2159.
61. Pencina M.J., D'Agostino R.B. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Strat Med 2004, 23:2109-2123.
62. Pencina M.J., D'Agostino R.B., D'Agostino R.B., Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172.
63. Burnett J.C., Kao P.C., Hu D.C., et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986, 231:1145-1147.
64. van Kimmenade R.R.J., Januzzi J.L. Emerging biomarkers in heart failure. Clin Chem 2012, 58:127-138.
65. Maisel A.S., Daniels L.B. Breathing not properly 10 years later. J Am Coll Cardiol 2012, 60:277-282.
66. Maisel A., Mueller C., Nowak R., et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010, 55:2062-2076.
67. Shah R.V., Truong Q.A., Gaggin H.K., et al. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J 2012, 33:2197-2205.
68. Sabatine M.S., Morrow D.A., de Lemos J.A., et al. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation 2012, 125:233-240.
69. Januzzi J.L., Camargo C.A., Anwaruddin S., et al. The N-terminal Pro BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am J Cardiol 2005, 95:948-954.
70. Di Angelantonio E., Chowdhury R., Sarwar N., et al. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 2009, 120:2177-2187.
71. Wang T.J., Larson M.G., Levy D., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004, 350:655-663.
72. Owens A.T., Jessup M. The year in heart failure. J Am Coll Cardiol 2012, 60:359-368.
73. Felker G.M., Hasselblad V., Hernandez A.F., O'Connor C.M. Biomarker-guided therapy in chronic heart failure: a meta-analysis or randomized controlled trials associated with a significant reduction in all-cause mortality compared to usual care in patients with chronic heart failure. Am Heart J 2009, 158:422-430.
74. Porpakkham P., Porpakkham P., Zimmet H., Billah B., Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med 2010, 170:507-514.
75. Sabatine M.S., Morrow D.A., Higgins L.J., et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008, 117:1936-1944.
76. Ky B., French B., McCloskey K., et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011, 4:180-187.
77. Ky B., French B., Levy W.C., Sweitzer N.K. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail 2012, 5:183-190.
78. Apple F.S., Collinson P.O. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012, 58:54-61.
79. Missov E., Calzolari C., Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation 1997, 96:2953.
80. La Vecchia L., Mezzena G., Zanolla L., et al. Cardiac troponin I as diagnostic and prognostic marker in severe heart failure. J Heart Lung Transplant 2000, 19:644-652.
81. Latini R., Masson S., Anand I.S., et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007, 116:1242-1249.
82. Tentzeris I., Jarai R., Farhan, et al. Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure. Eur J Heart Fail 2011, 13:726-733.
83. Pascual-Figal D.A., Manzano-Fernandez S., Boronat M., et al. Soluble ST2, high sensitivity troponin T and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 2011, 13:718-725.
84. Januzzi J.L., Filippatos G., Nieminen M., Gheorghiade M. Troponin elevation in patients with heart failure. Eur Heart J 2012, 33:2265-2271. for the Third Universal Definition of Myocardial Infarction Global Task Force, Heart Failure Section.
85. Felker G.M., Hasselblad V., Tang W.H.W., et al. Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. Eur J Heart Fail 2012, 14:1257-1264.
86. O'Connor C.M., Fiuzat M., Lombardi C., et al. Impact of serial troponin release on outcomes in patients with acute heart failure. Analysis from the PROTECT pilot study. Circ Heart Fail 2011, 4:724-732.
87. Masson S., Anand I., Favero C., et al. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure. Circulation 2012, 125:280-288.
88. Omland T., de Lemos J.A., Sabatine M.S., et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009, 361:2538-2547.
89. deFilippi C.R., de Lemos J.A., Christenson R.H., et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010, 304:2494-2502.
90. Saunders J.T., Nambi V., de Lemos J.A., et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk In Communities study. Circulation 2011, 123:1367-1376.
91. Zannad F., Rossignol P., Iraqi W. Extracellular matrix fibrotic markers in heart failure. Heart Fail Rev 2010, 15:319-329.
92. Zile M.R., DeSantis S.M., Baicu C.F., et al. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail 2011, 4:246-256.
93. Biolo A., Fisch M., Balog J., et al. Episodes of acute heart failure syndrome are associated with increased levels of troponin and extracellular matrix markers. Circ Heart Fail 2010, 3:44-50.
94. Zannad F., Alla F., Doucett B., Perez A., Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 2000, 102:2700-2706.
95. Iraqi W., Rossignol P., Angioi M., et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation 2009, 119:2471-2479.
96. Elster S.K., Braunwald E., Wood H.F. A study of C-reactive protein in the serum of patients with congestive heart failure. Am Heart J 1956, 51:533-541.
97. Bozkurt B., Mann D.L., Deswal A. Biomarkers of inflammation in heart failure. Heart Fail Rev 2010, 15:331-341.
98. Cesari M., Penninx B.W., Newman A.B., et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003, 108:2317-2322.
99. Vasan R.S., Sullivan L.M., Roubenoff R., et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction. Circulation 2003, 107:1486-1491.
100. Jougasaki M., Burnett J.C. Adrenomedullin: potential in physiology and pathophysiology. Life Sci 2000, 66:855-872.
101. Maisel A., Mueller C., Nowak R.M., et al. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea. J Am Coll Cardiol 2011, 58:1057-1067.
102. von Haehling S., Filippatos G.S., Papassotiriou J., et al. Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail 2010, 12:484-491.
103. Maisel A., Xue Y., Shah K., et al. Increased 90-day mortality in patients with acute heart failure with elevated copeptin. Circ Heart Fail 2011, 4:613-620.
104. Maisel A.S., Mueller C., Fitzgerald R., et al. Prognostic utility of plasma neutrophil gelatinase-associated lipcalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail 2011, 13:846-851.
105. Cruz D.N., Fard A., Clementi A., et al. Role of biomarkers in the diagnosis and management of cardio-renal syndromes. Semin Nephrol 2012, 32:79-92.
106. Damman K., Van Veldhuisen D.J., Navis G., et al. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart 2010, 96:1297-1302.
107. Connick M., Ishani A. Renal biomarkers of kidney injury in cardiorenal syndrome. Circ Heart Fail Rep 2011, 8:99-105.
108. Arab S., Gramolini A.O., Ping P., et al. Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. J Am Coll Cardiol 2006, 48:1733-1741.
109. Mebazaa A., Vanpoucke G., Thomas G., et al. Unbiased plasma proteomics for novel diagnostic biomarkers in cardiovascular disease: identification of quiescin Q6 as a candidate biomarker of acutely decompensated heart failure. Eur J Heart Fail 2012 June 24, [E-pub ahead of print].
110. Piran S., Liu P., Morales A., Hershberger R.E. Where genome meets phenome: rationale for integrating genetic and protein biomarkers in the diagnosis and management of dilated cardiomyopathy and heart failure. J Am Coll Cardiol 2012, 60:283-289.
111. Ng L.L., Pathik B., Loke I.W., et al. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. Am Heart J 2006, 152:94-101.
112. Pascual-Figal D.A., Manzano-Fernandez S., Boronat M., et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur Heart J 2011, 13:718-725.
113. Rehman S.U., Martinez-Rumayan A., Mueller T., Januzzi J.L. Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Clinica Chimica Acta 2008, 392:41-45.
114. van Kimmenade R.R., Januzzi J.L., Ellinor P.T., et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin 3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006, 48:1217-1224.
115. Velagaleti R.S., Goma P., Larson M.G., et al. Multimarker approach for the prediction of heart failure incidence in the community. Circulation 2010, 122:1700-1706.
116. Zethulius B., Berglund L., Sundstrom J., et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008, 358:2107-2116.
117. Lindenfeld J., Albert N.M., Boehmer J.P., et al. HFSA 2010 comprehensive heart failure practice guideline. J Cardiac Fail 2010, 16:e1-e194.
118. Jessup M., Abraham W.T., Caset D.E., et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults. Circulation 2009, 119:1977-2016.
119. Redfield M.M., Borlaug B.A., Lewis G.D., et al. Phosphodiesterase-5 inhibition in diastolic heart failure: the RELAX trial rationale and design. Circ Heart Fail 2012, 5:653-659.
120. Desai A.S., Lewis E.F., Li R., et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 2011, 162:966-972.
121. Solomon S.D., Zile M., Pieske B., et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012, 380:1387-1395.
122. Felker G., Pang P.S., Adams K.F., et al. Clinical trials of pharmacological therapies in acute heart failure syndromes. Lessons learned and directions forward. Circ Heart Fail 2010, 3:314-325.
123. Massie B.M., O'Connor C.M., Metra M., et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010, 363:1419-1428.
124. O'Connor C.M., Starling R.C., Hernandez A.F., et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011, 365:32-43.
125. Konstam M.A., Gheorghiade M., Burnett J.C., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure. The EVEREST outcome trial. JAMA 2007, 297:1319-1331.
126. Pang P.S., Konstam M.A., Krasa H.B., et al. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J 2009, 30:2233-2240.
127. Teerlink J.R., Metra M., Felker G.M., et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009, 373:1429-1439.
128. Teerlink J.R., Cotter G., Davison B.A., et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013, 381:29-39.
129. Hasenfuss G., Teerlink J.R. Cardiac inotropes: current agents and future directions. Eur Heart J 2011, 32:1838-1845.
130. Movessian M., Stehlik J., Vandeput F., Bristow M.R. Phosphodiesterase inhibition in heart failure. Heart Fail Rev 2009, 14:255-263.
131. Aronson D., Krum H. Novel therapies in acute and chronic heart failure. Pharmacol Ther 2012, 135:1-17.
132. Parissis J.T., Rafouli-Stergiou P., Parakevaidis I., Mebazaa A. Levosimendan: from basic science to clinical practice. Heart Fail Rev 2009, 14:165-175.
133. Delaney A., Bradford C., McCaffrey J., Bagshaw S.M., Lee R. Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomized controlled trials. Int J Cardiol 2010, 138:281-289.
134. Malik F.I., Hartman J.J., Elias K.A., et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 2011, 331:1439-1443.
135. Teerlink J.R., Clarke C.P., Saikali K.G., et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet 2011, 378:667-675.
136. Cleland J.G.F., Teerlink J.R., Senior R., et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 2011, 378:676-683.
137. Ait M.Y., Toth A., Cassan C., et al. Beneficial effects of SR33805 in failing myocardium. Cardiovasc Res 2011, 91:412-419.
138. Toischer K., Lahnart S.E., Tenderich G., et al. K201 improves aspects of the contractile performance of human failing myocardium via reduction in Ca2+ leak from the sarcoplasmic reticulum. Basic Res Cardiol 2010, 105:279-287.
139. Kushnir A., Marks A.R. The ryanodine receptor in cardiac physiology and disease. Adv Pharmacol 2010, 59:1-30.
140. Brinks H., Rohde D., Voelkers M., et al. S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes. J Am Coll Cardiol 2011, 58:966-973.
141. Lehnart S.E., Wehrens X.H., Reiken S., et al. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 2005, 123:535-536.
142. Wehrens X.H., Lehnart S.E., Huang F., et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 2003, 113:829-840.
143. Shan J., Betzenhauser M.J., Kishnir A., et al. Role of chronic ryanodine receptor phosphorylation in heart failure and β-adrenergic receptor blockade in mice. J Clin Invest 2010, 120:4375-4387.
144. Lehnart S.E., Mongillo M., Bellinger A., et al. Leaky Ca2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. J Clin Invest 2008, 118:2230-2245.
145. Kranias E.G., Hajjar R.J. Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ Res 2012, 110:1646-1660.
146. DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res 2006, 53:399-406.
147. Swedberg K., Komajda M., Böhm M., et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010, 376:875-885.
148. Teerlink J.R. Ivabradine in heart failure-no paradigm SHIFT...yet. Lancet 2010, 376:847-849.
149. Lewis G.D., Lachmann J., Camuso J., et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007, 115:59-66.
150. Lewis G.D., Shah R., Shahzad K., et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007, 116:1555-1562.
151. Guazzi M., Vicenzi M., Arena R., Guazzi M.D. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure. Results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 2011, 4:8-17.
152. Lindman B.R., Zajarias A., Madrazo J.A., et al. Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis. Circulation 2012, 125:2353-2362.
153. Leri A., Kajstura J., Anversa P. Cardiac stem cells and mechanisms of myocardial regeneration. Physiol Rev 2005, 85:1373-1416.
154. Bergmann O., Bhardwaj R.D., Bernard S., et al. Evidence for cardiomyocyte renewal in humans. Science 2009, 324:98-102.
155. Kajstura J., Leri A., Finato N., et al. Myocyte proliferation in end-stage cardiac failure in humans. Proc Natl Acad Sci USA 1998, 95:8801-8805.
156. Jeevanantham V., Butler M., Saad A., Abdel-Latif A., Zuba-Surma E.K., Dawn B. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters. A systematic review and meta-analysis. Circulation 2012, 126:551-568.
157. Bolli R., Chucgh A.R., D'Amario D., et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011, 378:1847-1857.
158. Chugh A.R., Beache G.M., Loughran J.H., et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial. Circulation 2012, 126(Suppl 1):S54-S64.
159. Makkar R.R., Smith R.R., Cheng K., et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 2012, 379:895-904.
160. Rose E.A., Gellins A.C., Moskowitz A.J., et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001, 345:1435-1443.
161. Slaughter M.S., Rogers J.G., Milano C.A., et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009, 361:2241-2251.
162. Park S.J., Milano C.A., Tatooles A., et al. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail 2012, 5:241-248.
163. Eckman P.M., John R. Bleeding and thrombosis in patients with continuous-flow ventricular assist devices. Circulation 2012, 125:3038-3047.
164. Kato T.S., Chokshi A., Singh P., et al. Effects of continuous-flow versus pulsatile-flow left ventricular assist devices on myocardial unloading and remodeling. Circ Heart Fail 2011, 4:546-553.
165. Williams M.L., Trivedi J.R., McCants K.C., et al. Heart transplant vs left ventricular assist device in heart transplant-eligible patients. Ann Thorac Surg 2011, 91:1330-1334.
166. Kirklin J.K., Naftel D.C., Pagani F.D., et al. Long-term mechanical circulatory support (destination therapy): on track to compete with heart transplantation?. J Thorac Cardiovasc Surg 2012, 144:584-603.
167. Kirklin J.K., Naftel D.C., Kormos R.L., et al. The fourth INTERMACS annual report: 4000 implants and counting. J Heart Lung Transplant 2012, 31:117-126.
168. Attisani M., Centofanti P., Torre M.L., et al. Advanced heart failure in critical patients (INTERMACS 1 and 2 levels): ventricular assist devices or emergency transplantation?. Interact Cardiovasc Thorac Surg 2012, 15:678-684.
169. Cleveland J.C., Naftel D.C., Reece T.B., et al. Survival after biventricular assist device implantation: an analysis of the Interagency Registry for Mechanically Assisted Circulatory Support database. J Heart Lung Transplant 2011, 30:862-869.
170. Aaronson K.D., Slaughter M.S., Miiller L.W., et al. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation 2012, 125:3191-3200.
171. Ambardekar A.V., Buttrick P.M. Reverse remodeling with left ventricular assist devices. A review of clinical, cellular, and molecular effects. Circ Heart Fail 2011, 4:224-233.
172. Hall J.L., Fermin D.R., Birks E.J., et al. Clinical, molecular, and genomic changes in response to a left ventricular assist device. J Am Coll Cardiol 2011, 57:641-652.
173. Zafeiridis A., Jeevanandam V., Houser S.R., Margulies K.B. Regression of cellular hypertrophy after left ventricular assist device support. Circulation 1998, 98:656-662.
174. Torre-Amione G., Stetson S.J., Youker K.A., et al. Decreased expression of tumor necrosis factor-α in failing human myocardium after mechanical circulatory support: a potential mechanisms for cardiac recovery. Circulation 1999, 100:1189-1193.
175. Dipla K., Mattiello J.A., Jeevanandam V., Houser S.R., Margulies K.B. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation 1998, 97:2316-2322.
176. Klotz S., Barbone A., Reiken S., et al. Left ventricular assist device support normalizes left and right ventricular beta-adrenergic pathway properties. J Am Coll Cardiol 2005, 45:668-676.
177. Mann D.L., Burkhoff D. Is myocardial recovery possible and how do you measure it?. Curr Cardiol Rev 2012, 14:293-298.
178. Maybaum S. Cardiac recovery during continuous-flow left ventricular assist device support. Some good news from across the Atlantic. Circulation 2011, 123:355-357.
179. Birks E.J., Tansley P.D., Hardy J., et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 2006, 355:1873-1884.
180. Birks E.J., George R.S., Hedger M., et al. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacologic therapy: a prospective study. Circulation 2011, 123:381-390.
181. Birks E.J., George R.S., Firouzi A., et al. Long-term outcomes of patients bridged to recovery versus patients bridged to transplantation. J Thorac Cardiovasc Surg 2012, 144:190-196.
182. Yacoub M.H., Terracciano C.M. Bridge to recovery and the search for decision nodes. Circ Heart Fail 2011, 4:393-395.
183. Dandel M., Weng Y., Siniawski H., et al. Pre-explant stability of unloading-promoted cardiac improvement predicts outcome after weaning from ventricular assist devices. Circulation 2012, 126(Suppl 1):S9-19.
184. Tilemann L., Ishikawa K., Weber T., Hajjar R.J. Gene therapy for heart failure. Circ Res 2012, 110:777-793.
185. Shah A.S., Lilly R.E., Kypson A.P., et al. Intracoronary adenovirus-mediated delivery and overexpression of the beta(s)-adrenergic receptor in the heart: prospects for molecular ventricular assistance. Circulation 2000, 101:408-414.
186. del Monte F., Harding S.E., Dec G.W., Gwathmey J.K., Hajjar R.J. Targeting phospholamban by gene transfer in human heart failure. Circulation 2002, 105:904-907.
187. Kawase Y., Ly H., Prunier F., et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 2008, 51:1112-1119.
188. Jessup M., Greenberg B., Mancini D., et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID). Circulation 2011, 124:304-313.
189. Lan F., Liu J., Narsinh K.H., et al. Safe genetic modification of cardiac stem cells using a site-specific integration technique. Circulation 2012, 126 Suppl 1:S20-S28.
190. Noiseux N., Gnecchi M., Lopez-Ilasaca M., et al. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther 2006, 14:840-850.
191. Fischer K.M., Cottage C.T., Wu W., et al. Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinase. Circulation 2009, 120:2077-2087.
192. Hunt S.A., Baker D.W., Chin M.H., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001, 38:2101-2113.
193. Lloyd-Jones D.M., Hong Y., Labarthe D., et al. Defining and setting national goals for cardiovascular health promotion and disease reduction. The American Heart Association's Strategic Impact Goal through 2020 and Beyond. Circulation 2010, 121:586-613.
194. Thanassoulis G., Peloso G.M., Pencina M.J., et al. A genetic risk score is associated with incident cardiovascular disease and coronary artery calcium-the Framingham Heart Study. Circ Cardiovasc Genet 2012, 5:113-121.
195. Dunlay S.M., Eveleth J.M., Shah N.D., McNallan S.M., Roger V.L. Medication adherence among community-dwelling patients with heart failure. Mayo Clinic Proc 2011, 86:273-281.
196. Voora D., Ginsburg G.S. Clinical application of cardiovascular pharmacogenetics. J Am Coll Cardiol 2012, 60:9-20.
197. Musunuru K., Roden D.M., Boineau R., et al. Cardiovascular pharmacogenomics: current status and future directions-report of a National Heart, Lung, and Blood Institute Working Group. J Am Heart Assoc 2012, 1:e000554.
198. Damani S.B., Topol E.J. Emerging clinical applications in cardiovascular pharmacogenomics. Wiley Interdiscip Rev Syst Biol Med 2011, 3:206-215.
199. Ligett S.B., Cresci S., Kelly R.J., et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 2008, 14:510-517.